HopeStage
Back to all studies
TerminatedNCT00483535

Oral Contraceptive Interaction Study for GW273225

Medication studyAges 18–45United KingdomBipolarity
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
CambridgeSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 7, 2007
Recruitment status
Terminated
Enrollment listed in the registry
12
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT00483535
Official title
Show the full official title

An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects

Recruitment & locations

Terminated

Cambridge

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Does this study involve medication?

Yes. The study involves medication, including GW273225 and COC.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies